实盘配资

Be the most trusted biotech company

2021-11-24

Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia
2021-11-08

Henlius Announces Successful Completion of Phase 1 Clinical Trial of Pertuzumab Biosimilar HLX11
2021-10-13

First Subject Dosed in Phase 1 Clinical Trial of Henlius’ Novel Anti-LAG-3 mAb HLX26
2021-10-12

Henlius Announces Dr. Jean-Michel Gries as President of Hengenix
2021-09-30

First Patient Dosed in Phase 2 Clinical Trial of HLX22 Combo Therapy in Patients with HER2-positive Gastric Cancer
2021-09-28

Hepatocellular Carcinoma Phase 2 Clinical Study Results of a Novel anti-PD-1 mAb Serplulimab has been Selected for the Innovation Session at 2021 CSCO
2021-09-26

Henlius Presents Results from Phase 2 Clinical Study of Its Novel anti-PD-1 mAb Serplulimab in Patients with Advanced Cervical Cancer at 2021 CSCO
2021-09-17

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
2021-08-18

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation